Screening for asymptomatic coronary artery disease in patients with diabetes mellitus: A systematic review and meta-analysis of randomized trials by Christophe Bauters & Gilles Lemesle
RESEARCH ARTICLE Open Access
Screening for asymptomatic coronary
artery disease in patients with diabetes
mellitus: A systematic review and meta-
analysis of randomized trials
Christophe Bauters1,2,3,4* and Gilles Lemesle1,3,4
Abstract
Background: Screening diabetic patients for the presence of asymptomatic coronary artery disease (CAD) may
potentially impact therapeutic management and outcome. We performed a systematic review and meta-analysis of
randomized trials addressing this question.
Methods: We searched the PubMed database for studies reporting a randomized comparison of systematic
screening for CAD in diabetic patients versus no systematic screening. The screening protocols were variable with
the use of exercise electrocardiogram test, or stress echocardiography, or nuclear test, or coronary computed
tomography angiography.
Results: The final analysis included 5 randomized studies and 3,314 patients altogether. The screening strategy had
no detectable impact on outcome with odds ratios (OR) [95 % confidence interval (CI)] of 1.00 [0.67–1.50], 0.72
[0.33–1.57], 0.71 [0.40–1.27], and 0.60 [0.23–1.52] for all-cause death, cardiovascular death, non-fatal myocardial
infarction, and the composite cardiovascular death or non-fatal myocardial infarction, respectively. Protocol-related
coronary procedures were relatively infrequent in screened patients: coronary angiography was performed in 8 % of
the cases, percutaneous coronary intervention in 2.5 %, and coronary artery bypass surgery in 1.5 %. There was no
evidence for an effect of screening on the use of statins (OR = 1.19 [0.94–1.51]), aspirin (OR = 1.02 [0.83–1.25]), or
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR = 0.97 [0.79–1.19]).
Conclusion: The present analysis shows no evidence for a benefit of screening diabetic patients for the presence
of asymptomatic CAD. The proportion of patients who undergo myocardial revascularization as a consequence of
screening was low.
Keywords: Diabetes mellitus, Coronary artery disease, Screening, Randomized study, Stress test, Coronary
angiography, Percutaneous coronary intervention, Coronary artery bypass surgery
Background
Diabetes mellitus (DM) is a major risk factor for the devel-
opment of coronary artery disease (CAD) [1]. CAD is
frequently asymptomatic in diabetic patients and is often
diagnosed when an acute myocardial infarction (MI)
occurs [2]; these acute events are frequently responsible of
irreversible myocardial damage, even when modern thera-
peutic strategies are used [3]. Moreover, when the diagno-
sis of CAD is made, the prognosis of diabetic patients is
worse than that of non-diabetic patients [4–7]. Since an
early detection of the disease may potentially impact
therapeutic strategies and prevent cardiac events, there
has for long been interest in the screening of diabetic
patients for the presence of asymptomatic CAD [8, 9]. In
2009 however, the report of the Detection of Ischemia in
Asymptomatic Diabetics (DIAD) study has modified the
perception of the benefit of this approach by showing
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similar rates of cardiac events in the screening and the
control groups [10]. Although DIAD was a breakthrough
study with rapid incorporation into the guidelines, it was
acknowledged that, due to the low rate of events overall,
the power of the study to exclude a difference in outcome
was limited. Since then, several other studies randomizing
screening strategies in diabetic populations have been
published, including very recently [11]. In the present
paper, our aim was to perform a systematic review and




The PubMed database was searched for eligible studies
with no restriction of time in January 2016 by using the
terms « (((diabetes) AND coronary) AND screening)
AND “randomized controlled trial” [Publication Type] »
and the filters « Humans » and « English ». Two investi-
gators (CB and GL) independently checked retrieved
titles and abstracts for eligibility and relevant full texts
were systematically retrieved for further detailed assess-
ment. The search procedure was repeated in Science
Direct and ISI Web of Knowledge (All databases). Major
reviews regarding screening for CAD in diabetic patients
were also hand-searched. Cross-references and quoted
papers were checked to identify other relevant studies.
The retrieved studies were examined to exclude overlap-
ping data. Unpublished data and meeting abstracts were
not considered for the present analysis because they
could not provide adequately detailed data and their re-
sults might not be final.
Study eligibility
Studies were eligible only if they reported a randomized
comparison of systematic screening for CAD in diabetic
patients versus no systematic screening. Inclusion criteria
were: (i) prospective randomized study; (ii) comparison of
screening for CAD with exercise electrocardiogram test
(ETT), or stress echocardiography, or nuclear stress test, or
coronary computed tomography angiography (CCTA),
versus no screening; (iii) in asymptomatic diabetic patients
with no evidence of CAD; (iv) with a follow-up > 1 year; (v)
with availability of at least one of the following events at
follow-up: all-cause death, cardiovascular death, non-fatal
MI, the composite of cardiovascular death or non-fatal MI.
Exclusion criteria were: (i) cohort studies; (ii) studies per-
formed in patients with prior CAD; (iii) studies with over-
lapping data; (iv) studies performed in animals; (v) studies
performed without final report and only abstracts available.
Data extraction
The following information was extracted from each
study: study name and first author; number of patients;
monocentric or multicentric study; geographic area;
period of inclusion; duration of follow-up; inclusion
criteria; exclusion criteria; screening protocol; treatment
plan if screening test was abnormal; baseline characteristics
of the patients for the different studies (age, body-mass
index, gender, smoking, systolic and diastolic blood pres-
sure, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, type of DM, duration
of DM, insulin treatment, levels of glycated hemoglobin,
retinopathy, peripheral vascular disease, statin use at base-
line, aspirin use at baseline, angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker (ACE/ARB) use at
baseline); number of patients with all-cause death, cardio-
vascular death, non-fatal MI, the composite of cardiovascu-
lar death or non-fatal MI, in the screening groups versus
the control groups at follow-up; number of patients receiv-
ing statins, aspirin, ACE/ARB in the screening groups
versus the control groups at follow-up; number of patients
with abnormal screening; number of patients with
protocol-related coronary procedures (coronary angiog-
raphy, percutaneous coronary intervention (PCI), coronary
artery bypass surgery (CABG)) in the screening group.
Data synthesis and statistical analysis
Statistical analysis was performed using STATA version
14.0, StataCorps, College Station, Texas. Odds ratios
(ORs) and 95 % confidence intervals (CI) of all-cause
death, cardiovascular death, non-fatal MI, cardiovascular
death or non-fatal MI, statin use, aspirin use, ACE/ARB
use were calculated using the metan command. Overall
estimates of effect were calculated with a random-effects
model. Between-study statistical heterogeneity was
assessed by using the Cochran Q chi-square and the I2
test. Small-study effect was assessed visually by examin-
ing funnel plots of each trial effect size against the
standard error.
Results
Search results and study selection
We found 926 citations in PubMed. Among 21 poten-
tially relevant studies for which a detailed assessment of
the full-text was performed, 16 were excluded. The rea-
sons for exclusion were: studies not focusing on screen-
ing for CAD in diabetic patients (n = 4), non randomized
studies (n = 3), studies comparing two screening strat-
egies with no control group (n = 1), studies comparing 2
treatment strategies after systematic screening (n = 2),
and studies with overlapping data (n = 6). We finally in-
cluded 5 randomized comparisons of systematic screen-
ing for CAD in asymptomatic diabetic patients versus
no systematic screening: the Faglia et al. study [12], the
DIAD study [10], the Do You Need to Assess Myocar-
dial Ischemia in Type-2 diabetes? (DYNAMIT) study
[13], the FACTOR-64 study [14], and the Does coronary
Bauters and Lemesle BMC Cardiovascular Disorders  (2016) 16:90 Page 2 of 11
Atherosclerosis Deserve to be Diagnosed earlY in Dia-
betic patients? (DADDY-D) study [11]. The search
procedure was repeated in ScienceDirect and ISI Web of
Knowledge; we found no additional studies that met our
inclusion criteria. Further searches using cross-references
and quoted papers as well as analyses of review papers on
screening for CAD in diabetic patients did not identify
other studies. The study selection process is summarized in
Fig. 1.
Studies and patients characteristics
Table 1 shows the characteristics of the five included
studies. The number of patients ranged from 141 to
1,123 (total = 3,314). All studies were randomized; re-
cruitment was monocentric in the Faglia et al. and in
the DADDY-D studies, and multicentric in DIAD,
DYNAMIT, and FACTOR-64. Overall, the inclusion
periods varied from 1998 to 2013 and the follow-up
time was in the 3 to 5-year range. With the exception
of FACTOR-64 in which there was a small proportion
(12 %) of patients with type 1 DM, inclusion was lim-
ited to patients with type 2 DM. Inclusion criteria are
summarized in Table 1. The Faglia et al. and DYNA-
MIT studies focused on diabetic patients with other
risk factors; DADDY-D included diabetic patients with
high cardiovascular risk score. The screening proto-
cols were variable with the use of ETT, stress echo-
cardiography, or nuclear stress test to detect
myocardial ischemia; in the Faglia at al. study, two
tests were used; in FACTOR-64, CCTA was used to
directly test for the presence of coronary atheroscler-
osis rather than assessing ischemia. Treatment plans
in case of abnormal screening test were also variable.
In Faglia et al., FACTOR-64 and DADDY-D, coronary
angiography was recommended, while in DIAD and
DYNAMIT, subsequent investigations were left at the
decision of the physician or cardiologist. The overall
quality assessment of the different studies was good
(Additional file 1: Table S1).
As shown in Table 2, the mean age varied between 58
and 64 years and the proportion of women varied be-
tween 20 % and 48 %. The mean duration of DM ranged
from 8 to 13 years and the mean HbA1c from 7.0 to
8.7 %. The distribution of other coronary risk factors
among studies is summarized in Table 2 as well as the
use of insulin, statins, aspirin and ACE/ARB prior to
randomization.
Effect of screening on clinical events during follow-up
Follow-up data were available in 4 studies for all-
cause death, cardiovascular death, and non-fatal MI,
and in three studies for the combined endpoint of
cardiovascular death or non-fatal MI. The proportion
of patients with events during follow-up were 3.5,
1.5, 2.4, and 3.9 %, for all-cause death, cardiovascu-
lar death, non-fatal MI, and the composite cardio-
vascular death or non-fatal MI, respectively. Figure 2
shows forest plots for the effect of screening on clinical
events. In the pooled analysis, there was no impact of
screening on all-cause death (OR = 1.00 [0.67–1.50], P =
0.996), cardiovascular death (OR = 0.72 [0.33–1.57], P =
0.407), non-fatal MI (OR = 0.71 [0.40–1.27], P = 0.246),
and the composite cardiovascular death or non-fatal MI
(OR = 0.60 [0.23–1.52], P = 0.280). The funnel plots
Fig. 1 Flow chart of the study selection process
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Table 1 Description of the studies included in the meta-analysis
Faglia et al. (2005) DIAD (2009) DYNAMIT (2011) FACTOR-64 (2014) DADDY-D (2015)
Number of
patients
141 1123 631 899 520
Design Randomized Randomized Randomized Randomized Randomized
Monocenter Multicenter Multicenter Multicenter Monocenter













Follow-up 4.3 years 5 years 3.5 years 4 years 3.6 years
Inclusion criteria - Type 2 DM
- 45–75 years
- At least 2 of the following:








4. albumin excretion >30
mg/24 h
5. family history of CAD







- Type 2 DM
- 55–75 years
- At least 2 of the following:
1. albumin excretion >30mg/L
or >30 mg/24 h
2. treated or untreated
hypertension
3. treated or untreated
lipid abnormality
4. peripheral arterial disease
5. prior transient ischemic
accident
6. smoking
7. family history of CAD
- Type 1 or type 2 DM
- Men ≥50 years or women
≥55 years with DM documented
for ≥3 years, or men ≥40 years or
women ≥45 years with DM
documented for ≥5 years
- Use of antidiabetic medication
for ≥1 year prior to enrollment
- Type 2 DM documented
for ≥1 year
- 50–70 years
- Normal sinus rhythm
on ECG
- Cardiovascular risk score
≥10 % according to
Italian risk chart [11]








- Stress test or coronary
angiography within
the prior 3 years
- History of MI, heart
failure, or coronary
revascularization
- Abnormal results of
rest ECG
- Any clinical indication
for stress testing
- Active bronchospasm
precluding the use of
adenosine
- Limited life expectancy
due to cancer or
end-stage renal or
liver disease
- History of MI, CAD, or stroke
- Previous positive stress test or
myocardial perfusion imaging
- Previous negative stress test or
myocardial perfusion imaging




- Treatment with an
investigational drug within
30 days
- Therapy or condition posing
a risk for adherence to study
requirements
- Pregnancy, lactation, or
childbearing potential without
effective contraception




- Prior CAD or heart failure
- ETT or other stress testing
or coronary angiography
performed within 1 year
- ECG showing left bundle
branch block or ST
depression >1 mm or a
Q wave































ETT or dipyridamole SPECT
in patients unable to perform
the exercise test, with a
sub-maximal negative exercise
test result or with ECG
abnormalities impairing the
interpretation of the exercise test.
CCTA screening. If the serum
creatinine level was 2.0 mg/dL
or greater for men or 1.8 mg/dL
or greater for women, or if
some other contraindication
to performing CCTA was
present, screening was
performed without contrast,






All subjects with ≥1 test
positive were advised to
undergo coronary angiography.
All subjects with positive screening
had to undergo cardiological
consultation and follow-up.
All the subjects with negative
screening and the subjects in the
control arm did not undergo any
cardiological workup in the absence
of any cardiac symptoms.
None.











were left at the cardiologist’s
decision.
Based on CCTA results, patients
with severe stenosis were
recommended to undergo
coronary angiography; patients
with moderate stenosis were
recommended to receive stress
cardiac imaging.
Standard medical management
was recommended to patients
of the control group and to
patients with normal CCTA.
Patients with abnormal CCTA
or a CAC score >10 were
recommended to begin aggressive
care to reduce risk factors [14].
Coronary angiography
was proposed to all
patients with positive ETT.
CAC coronary artery calcium, CAD coronary artery disease, CCTA coronary computed tomography angiography, DM diabetes mellitus, ECG electrocardiogram, ETT exercise electrocardiogram test, HDL high-density















Table 2 Description of the baseline characteristics of the patients in the different studies included in the meta-analysis
Faglia et al. (2005) DIAD (2009) DYNAMIT (2011) FACTOR-64 (2014) DADDY-D (2015)
Number of patients
- Screening 71 561 316 452 262
- Control 70 562 315 447 258
Age, y ± SD
- Screening 58.7 ± 8.3 60.7 ± 6.7 64.1 ± 6.4 61.5 ± 7.9 61.9 ± 4.8
- Control 61.5 ± 8.1 60.8 ± 6.4 63.7 ± 6.4 61.6 ± 8.4 62.0 ± 5.1
BMI, kg/m2 ± SD
- Screening 27.2 ± 5.1 31.1 ± 6.5 30.4 + 4.7 32.9 ± 6.8 29.6 ± 4.9
- Control 28.3 ± 4.6 31.0 + 6.1 30.8 ± 5.3 33.4 ± 7.1 30.6 ± 7.2
Women
- Screening 39 % 48 % 45 % 48 % 20 %
- Control 47 % 45 % 46 % 47 % 20 %
Smokersa
- Screening 65 % 10 % 17 % 17 % 40 %
- Control 79 % 9 % 15 % 15 % 38 %
Systolic BP, mmHg ± SD
- Screening 143 ± 19 133 ± 17 – 129 ± 12 140 ± 15
- Control 142 ± 17 132 ± 16 – 131 ± 11 141 ± 15
Diastolic BP, mmHg ± SD
- Screening 86 ± 11 80 ± 9 – 74 ± 8 82 ± 7
- Control 84 ± 10 79 ± 8 – 74 ± 8 81 ± 7
LDL-C, mg/dL ± SD
- Screening – 114 ± 32 – 86 ± 29 125 ± 37
- Control – 114 ± 33 – 88 ± 33 119 ± 33
HDL-C, mg/dL ± SD
- Screening 49 ± 15 50 ± 15 – 45 ± 14 42 ± 11
- Control 46 ± 15 49 ± 15 – 45 ± 13 42 ± 12
Triglycerides, mg/dL ± SD or [95 % CI]
- Screening 154 ± 105 172 ± 118 – 144 [99–201] 163 ± 140
- Control 161 ± 88 168 ± 101 – 132 [92–198] 161 ± 96
Type 2 diabetes
- Screening 100 % 100 % 100 % 88 % 100 %
- Control 100 % 100 % 100 % 88 % 100 %
Duration of DM, y ± SD
- Screening 11.6 ± 10.6 8.2 ± 7.1 – 12.3 ± 9.2 9.9 ± 6.7
- Control 11.3 ± 10.3 8.9 ± 6.9 – 13.5 ± 10.7 10.0 ± 6.2
Insulin
- Screening 11 % 24 % – 43 % 23 %
- Control 14 % 22 % – 43 % 21 %
HbA1c, % ± SD
- Screening 8.6 ± 2.3 7.2 ± 1.6 8.6 ± 2.2 7.4 ± 1.4 7.7 ± 1.4
- Control 8.4 ± 1.9 7.0 ± 1.5 8.7 ± 2.0 7.5 ± 1.4 7.8 ± 3.1
Retinopathy
- Screening 56 % 14 % – – 14 %
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Table 2 Description of the baseline characteristics of the patients in the different studies included in the meta-analysis (Continued)
- Control 59 % 16 % – – 17 %
Peripheral vascular disease
- Screening – 9 % 14 % – 5 %
- Control – 9 % 14 % – 7 %
Statins use (baseline)
- Screening 39 % 37 % – 77 % 49 %
- Control 30 % 41 % – 72 % 44 %
Aspirin use (baseline)
- Screening 13 % 43 % – 43 % 29 %
- Control 17 % 46 % – 41 % 26 %
ACE/ARB use (baseline)
- Screening 14 % 37 % – – 62 %
- Control 14 % 41 % – – 65 %
ACE/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, BMI body-mass index, BP blood pressure, CI confidence interval, DM diabetes
mellitus, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
adata are for smokers in Faglia et al. and DYNAMIT, current smokers in DIAD and DADDY-D, former or current smokers in FACTOR-64
Fig. 2 Effect of screening on all-cause death, cardiovascular death, non-fatal myocarial infarction (MI), the composite of cardiovascular death or non-fatal
MI. Odds ratios (OR) with 95 % confidence intervals (CI). For each study, the area of the box represents its contribution to the meta-analysis (weight).
Numbers of events are shown in the screening group and in the control group. Overall estimates of effects were calculated with a random effect model
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(Additional file 2: Figure S1) suggested asymmetry along
the treatment effect, indicating possible small-study effect.
Coronary angiography and revascularization
The results of the screening and the early protocol-
related coronary procedures in the screening groups are
summarized in Table 3 and Fig. 3. The number of
patients with abnormal screening varied between 8 %
and 21 %. The proportion of patients with abnormal
screening who underwent coronary angiography varied
between 22 % and 93 % (Table 3). Overall, coronary
angiography related to a positive screening was per-
formed in 130 patients out of the 1,662 patients
randomized to screening (8 %). Among the 130 patients
with angiography, half underwent myocardial revascular-
ization, 40 by PCI and 25 by CABG, representing 2.5 %
and 1.5 % of the total number of screened patients, re-
spectively (Fig. 3).
Impact of screening on statin, aspirin and ACE/ARB use
Information on statins use after screening was available
in all five studies. As shown in Fig. 4, there was no
evidence in the pooled analysis for an increased use of
statins in screened patients (OR = 1.19 [0.94–1.51] (P =
0.158). Information on aspirin use after screening was
available in 4 studies. Likewise, as shown in Fig. 4, there
Table 3 Results of the screening procedures for the different studies included in the meta-analysis
Faglia et al. (2005) DIAD (2009) DYNAMIT (2011) FACTOR-64 (2014) DADDY-D (2015)
Number of patients in
the screening arm
71 561 316 452 262
Patients with positive
screening, n (%)
15 (21 %) 83 (15 %) – 76 (17 %)a 20 (8 %)
Patients with abnormalb
screening, n (%)
15 (21 %) 113 (20 %) 68 (22 %) 76 (17 %) 20 (8 %)
Coronary angiography related
to abnormal screening, n (%)
14 (20 %) 25 (4 %) 38 (12 %) 36 (8 %) 17 (6 %)
Proportion of patients with
abnormal screening who
underwent coronary angiography
14/15 = 93 % 25/113 = 22 % 38/68 = 56 % 36/76 = 47 % 17/20 = 85 %
Patients with significant CAD on
coronary angiography performed
subsequently to the initial
screening, n (%)
9 (13 %) 9 (2 %) – – 12 (5 %)
Proportion of patients with
coronary angiography who
had significant CAD
9/14 = 64 % 9/25 = 36 % – – 12/17 = 71 %
amoderate to severe coronary stenosis by CCTA
babnormal screening included patients with positive screening and patients with non-perfusion abnormality (ischemic ECG changes, transient left ventricle
dilation, or baseline left ventricle dysfunction) in the DIAD study; patients with positive screening and SPECT results showing small defects (uncertain results)
in the DYNAMIT study
Fig. 3 Coronary angiography and revascularization procedures in the screening arms of the 5 studies and in the pooled analysis. The proportions
of coronary angiography, PCI (percutaneous coronary interventions) and CABG (coronary artery bypass surgery) are expressed relative to the
number of patients undergoing screening
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was no evidence for an increased use of aspirin in
screened patients (OR = 1.02 [0.83–1.25] (P = 0.837).
Information on ACE/ARB use after screening was
available in three studies. Likewise, as shown in Fig. 4,
there was no evidence for an increased use of ACE/ARB
in screened patients (OR = 0.97 [0.79–1.19] (P = 0.780).
Fig. 4 Effect of screening on statin, aspirin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACE/ARB) use
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Discussion
A significant proportion of the diabetic patients with
no clinical evidence for CAD have abnormal stress
tests [8, 9, 15] and are at greater risk for cardiovascu-
lar events [16]. Screening for asymptomatic CAD in
these patients is intuitively attractive as this could poten-
tially lead to additional therapies (coronary revasculariza-
tion, intensification of preventive medications) and closer
follow-up. Several randomized trials have been performed
to answer to this clinical question [10–14]. However, the
cardiac event rates were significantly lower than originally
anticipated when these studies were designed [10, 13, 14]
and whether the strategy of systematic screening may im-
prove outcome is still a matter of debate [17, 18].
The present pooled analysis shows that systematic
coronary screening of asymptomatic diabetic patients
has no detectable impact on the subsequent risk of
all-cause death, cardiovascular death, non-fatal MI,
and the composite of cardiovascular death or non-
fatal MI.
In screened diabetic patients, protocol-related cor-
onary angiographies were relatively infrequent (8 %)
and myocardial revascularization was only performed
in one half of this group. Although revascularization
has not been shown to be superior to optimal med-
ical therapy in the overall population of stable CAD
patients with DM [19, 20], it has been suggested that
the subgroup with the most severe disease may
benefit from CABG [20, 21]. However, even if bene-
ficial for some individuals, CABG in this population
is very rare and its impact is unlikely to be detect-
able in the overall screened group. In the present
analysis, CABG was performed in 1.5 % of the
screened patients, a figure very similar to the 1 %
rate reported in a recent prospective cohort [16].
As far as medical prevention therapy is concerned,
our results show that statin, aspirin and ACE/ARB
use did not differ in the screening and control
groups at follow-up. This is probably related to the
fact that, nowadays, diabetic patients have a good
background of medical prevention irrespective of
CAD diagnosis. Indeed, it is generally accepted that
patients with DM have a risk approaching that of
CAD patients [22] and aggressive risk factor reduc-
tion is recommended for these patients [23]. The re-
duced plaque burden may consequently decrease the
risk of events [24].
The present study has several limitations. Firstly,
even in the pooled analysis, the number of events
was low and the power to exclude a difference be-
tween groups is limited. However, this demonstrates
the reasonably good prognosis of asymptomatic dia-
betic patients candidate to screening, a useful infor-
mation in clinical practice. Secondly, the study
protocols differed widely. Although all included stud-
ies were designed as comparisons of screening for
CAD versus no screening, the screening methods
were variable (ETT, stress echocardiography, nuclear
stress test, or CCTA) and have different sensitivities,
specificities, and predictive values for the detection of
CAD. The screening methods also provide different
information for physicians (indicators of myocardial
ischemia, anatomical information). It should thus be ac-
knowledged that this is a limitation of our study, and that
- if realized in the future - an adequately powered study
specifically focusing on one screening method may be
positive. In addition, some studies included a treatment
plan in case of abnormal screening while, in other studies,
the results of the screening were communicated to the
personal physician or cardiologist who decided if subse-
quent investigations and treatments were needed. As a
consequence, the rate of coronary angiography in case of
positive screening varied from nearly 100 % (when indi-
cated by the protocol) to only 20 % (when left at the physi-
cian’s decision). Regarding medical prevention, the
recommendation to provide aggressive care to reduce risk
factors in patients with abnormal CCTA or CAC score in
FACTOR-64 is probably the explanation for the increased
statin use at follow-up which was solely observed in this
study (Fig. 4). Finally, the limited number of studies pre-
cluded to analyze how study-level covariates may impact
on the benefit of screening.
Conclusions
In conclusion, diabetic patients included in randomized
comparisons of CAD screening versus no screening have a
low risk of clinical events during follow-up. The present
analysis shows no evidence for a benefit of screening in
term of outcome. The proportion of patients who undergo
myocardial revascularization as a consequence of screening
is low; the percentage of patients undergoing CABG is in
the 1 % range. Overall, screening has no detectable impact
on the prescription of preventive medications including
statins, aspirin and ACE/ARB.
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